



Announcement Summary

Entity name

BIONOMICS LIMITED

Announcement Type

New announcement

Date of this announcement

Tuesday June 2, 2020

The Proposed issue is:

☒ A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +Security Code	+Security Description	Maximum Number of +securities to be issued
BNO	ORDINARY FULLY PAID	135,833,000

Proposed +issue date

Monday June 15, 2020

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

BIONOMICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

1.2 Registered Number Type

ABN

Registration Number

53075582740

1.3 ASX issuer code

BNO

1.4 The announcement is

☒ New announcement

1.5 Date of this announcement

Tuesday June 2, 2020

1.6 The Proposed issue is:

☒ A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 - Are any of the following approvals required for the placement or other type of issue?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

☒ Yes

7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
FIRB approval	Monday August 10, 2020	<input checked="" type="checkbox"/> Estimated	No

Comments

Shareholder and FIRB approval required for Second Placement, underwriting arrangements and issue of Warrants. Refer to announcement dated 2 June 2020.

No approval required for First Placement as described in announcement dated 2 June 2020.

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

☒ Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

☒ No

Details of +securities proposed to be issued

ASX +Security Code and Description

BNO : ORDINARY FULLY PAID

Maximum Number of +securities proposed to be issued

135,833,000



Purpose of the issue

Fund Clinical Trial & working capital.
First Placement* - 81,500,000 (within placement capacity)
Second Placement* - 54,333,000
Underwriting arrangements* £ up to 250,000,000
Warrants* £ 150,000,000 (convertible into 150,000,000 fully paid ordinary shares)
* in this Part 7B the above expressions are used as described in announcement dated 2 June 2020

Offer price details for retail security holders

In what currency is the cash consideration being paid?

AUD - Australian Dollar

What is the issue price per +security?

AUD 0.04000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

☒ Yes

Oversubscription & Scale back details

May a scale back be applied to this event?

☒ No

Part 7C - Timetable

7C.1 Proposed +issue date

Monday June 15, 2020

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

☒ Yes

7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

Monday August 10, 2020

7D.2 Is a party referred to in listing rule 10.11.1 participating in the proposed issue?

☒ No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

☒ No



7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

☒ No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

☒ No

7E.2 Is the proposed issue to be underwritten?

☒ No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

In relation to shares issued pursuant to the underwriting arrangements described in the announcement dated 2 June 2020, the principal material cost will be the issue of the Warrants referred to elsewhere in this Appendix 3B

Part 7F - Further Information

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

☒ No

7F.2 Any other information the entity wishes to provide about the proposed issue

No approval required the First Placement*
Approval required for the Second Placement*
Further shareholder approvals are to be sought in relation to the Warrants and the underwriting arrangements*
Refer to announcement dated 2 June 2020